Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Mercury Pharmaceuticals Ltd, Capital House, 85 King William Street, London EC4N 7BL, UK
Macrobid 100mg Prolonged-release Capsules.
| Pharmaceutical Form |
|---|
|
The 100mg capsule has an opaque blue cap and opaque yellow body and bears the monogram “GS 100”. |
Macrobid is a modified release, hard gelatin capsule containing the equivalent of 100mg of Nitrofurantoin in the form of nitrofurantoin macrocrystals and nitrofurantoin monohydrate.
Excipient(s) with known effect: Lactose 194.60 mg per capsule.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Nitrofurantoin |
Nitrofurantoin is a broad spectrum antibacterial agent, active against the majority of urinary pathogens. It is bactericidal in renal tissue and throughout the urinary tract. The wide range of organisms sensitive to the bacterial activity include Escherichia coli, Enteroccus faecalis, Klebsiella species, Enterobacter species, Staphylococcus species: (e.g. S. aureus, S. saprophyticus, S. epidermidis). |
| List of Excipients |
|---|
|
Macrobid Capsules contain: Talc Printing ink contains: Shellac |
There are two pack sizes, one consists of 14 capsules and the other is a sample pack containing 2 capsules. Not all pack sizes may be marketed.
Mercury Pharmaceuticals Ltd, Capital House, 85 King William Street, London EC4N 7BL, UK
PL 12762/0052
31/03/2000
| Drug | Countries | |
|---|---|---|
| MACROBID | Canada, Ireland, Israel, New Zealand, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
